Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information tech… Read more
Haemonetics Corporation (HAE) - Total Assets
Latest total assets as of December 2025: $2.49 Billion USD
Based on the latest financial reports, Haemonetics Corporation (HAE) holds total assets worth $2.49 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Haemonetics Corporation - Total Assets Trend (1992–2025)
This chart illustrates how Haemonetics Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Haemonetics Corporation - Asset Composition Analysis
Current Asset Composition (March 2025)
Haemonetics Corporation's total assets of $2.49 Billion consist of 38.2% current assets and 61.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $306.76 Million | 12.5% |
| Accounts Receivable | $202.66 Million | 8.3% |
| Inventory | $365.14 Million | 14.9% |
| Property, Plant & Equipment | $331.54 Million | 13.5% |
| Intangible Assets | $455.74 Million | 18.6% |
| Goodwill | $604.27 Million | 24.7% |
Asset Composition Trend (1992–2025)
This chart illustrates how Haemonetics Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Haemonetics Corporation's current assets represent 38.2% of total assets in 2025, a decrease from 54.2% in 1992.
- Cash Position: Cash and equivalents constituted 12.5% of total assets in 2025, up from 2.0% in 1992.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 42.0% of total assets, an increase from 4.0% in 1992.
- Asset Diversification: The largest asset category is goodwill at 24.7% of total assets.
Haemonetics Corporation Competitors by Total Assets
Key competitors of Haemonetics Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Haemonetics Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Haemonetics Corporation generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Haemonetics Corporation generates $6.84 in net profit.
Haemonetics Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.75 | 3.97 | 2.74 |
| Quick Ratio | 1.15 | 2.55 | 1.46 |
| Cash Ratio | 0.67 | 1.27 | 0.00 |
| Working Capital | $403.81 Million | $ 752.63 Million | $ 440.05 Million |
Haemonetics Corporation - Advanced Valuation Insights
This section examines the relationship between Haemonetics Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.95 |
| Latest Market Cap to Assets Ratio | 1.05 |
| Asset Growth Rate (YoY) | 11.6% |
| Total Assets | $2.45 Billion |
| Market Capitalization | $2.57 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Haemonetics Corporation's assets above their book value (1.05 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Haemonetics Corporation's assets grew by 11.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Haemonetics Corporation (1992–2025)
The table below shows the annual total assets of Haemonetics Corporation from 1992 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $2.45 Billion | +11.63% |
| 2024-03-31 | $2.20 Billion | +13.48% |
| 2023-03-31 | $1.93 Billion | +4.04% |
| 2022-03-31 | $1.86 Billion | +2.19% |
| 2021-03-31 | $1.82 Billion | +43.63% |
| 2020-03-31 | $1.27 Billion | -0.60% |
| 2019-03-31 | $1.27 Billion | +3.02% |
| 2018-03-31 | $1.24 Billion | -0.11% |
| 2017-03-31 | $1.24 Billion | -5.95% |
| 2016-03-31 | $1.32 Billion | -11.19% |
| 2015-03-31 | $1.48 Billion | -2.48% |
| 2014-03-31 | $1.52 Billion | +4.03% |
| 2013-03-31 | $1.46 Billion | +60.53% |
| 2012-03-31 | $910.63 Million | +9.28% |
| 2011-03-31 | $833.26 Million | +10.49% |
| 2010-03-31 | $754.14 Million | +16.08% |
| 2009-03-31 | $649.69 Million | +6.69% |
| 2008-03-31 | $608.95 Million | +6.32% |
| 2007-03-31 | $572.74 Million | +4.79% |
| 2006-03-31 | $546.54 Million | +16.84% |
| 2005-03-31 | $467.76 Million | +14.82% |
| 2004-03-31 | $407.39 Million | +13.41% |
| 2003-03-31 | $359.21 Million | -1.57% |
| 2002-03-31 | $364.92 Million | +5.68% |
| 2001-03-31 | $345.31 Million | -1.09% |
| 2000-03-31 | $349.11 Million | -2.05% |
| 1999-03-31 | $356.40 Million | +5.85% |
| 1998-03-31 | $336.70 Million | +4.08% |
| 1997-03-31 | $323.50 Million | +12.40% |
| 1996-03-31 | $287.80 Million | +2.60% |
| 1995-03-31 | $280.50 Million | +21.59% |
| 1994-03-31 | $230.70 Million | +27.95% |
| 1993-03-31 | $180.30 Million | +24.52% |
| 1992-03-31 | $144.80 Million | -- |